Identification of Axinellamines A and B as Anti-Tubercular Agents.
Emily J StrongLendl TanSasha HayesHayden WhyteRohan A DavisNicholas P WestPublished in: Marine drugs (2024)
Tuberculosis remains a significant global health pandemic. There is an urgent need for new anti-tubercular agents to combat the rising incidence of drug resistance and to offer effective and additive therapeutic options. High-throughput screening of a subset of the NatureBank marine fraction library ( n = 2000) identified a sample derived from an Australian marine sponge belonging to the order Haplosclerida that displayed promising anti-mycobacterial activity. Bioassay-guided fractionation of the organic extract from this Haplosclerida sponge led to the purification of previously identified antimicrobial pyrrole alkaloids, axinellamines A ( 1 ) and B ( 2 ). The axinellamine compounds were found to have a 90% minimum inhibitory concentration (MIC 90 ) of 18 µM and 15 µM, respectively. The removal of protein and complex carbon sources reduced the MIC 90 of 1 and 2 to 0.6 and 0.8 µM, respectively. The axinellamines were not toxic to mammalian cells at 25 µM and significantly reduced the intracellular bacterial load by >5-fold. These data demonstrate that axinellamines A and B are effective anti-tubercular agents and promising targets for future medicinal chemistry efforts.